
Claudia C Faria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7783978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-L1 tumor expression is associated with poor prognosis and systemic immunosuppression in glioblastoma. Journal of Neuro-Oncology, 2022, 156, 453-464.	2.9	2
2	The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary, 2022, 25, 363-382.	2.9	14
3	How Can Biobanks Help You in Your Research Projects?. Stroke, 2022, , STROKEAHA121036917.	2.0	0
4	<i>Cadherinâ€3</i> is a novel oncogenic biomarker with prognostic value in glioblastoma. Molecular Oncology, 2022, 16, 2611-2631.	4.6	4
5	Patient-derived models of brain metastases recapitulate human disseminated disease. Cell Reports Medicine, 2022, 3, 100623.	6.5	6
6	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	1.2	46
7	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
8	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
9	LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease. Neuro-Oncology Advances, 2021, 3, iii10-iii10.	0.7	0
10	Cadherin Expression and EMT: A Focus on Gliomas. Biomedicines, 2021, 9, 1328.	3.2	30
11	The Role of Biobanks in the Fight against COVID-19 Pandemic: The Portuguese Response. Acta Medica Portuguesa, 2021, 35, .	0.4	0
12	Medulloblastoma has a global impact on health related quality of life: Findings from an international cohort. Cancer Medicine, 2020, 9, 447-459.	2.8	11
13	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
14	Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nature Medicine, 2020, 26, 720-731.	30.7	141
15	EPEN-33. PHARMACOGENOMICS REVEALS SYNERGISTIC INHIBITION OF ERBB2 AND PI3K SIGNALING AS A THERAPEUTIC STRATEGY FOR EPENDYMOMA. Neuro-Oncology, 2020, 22, iii314-iii314.	1.2	0
16	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nature Communications, 2019, 10, 4343.	12.8	200
17	EPEN-08. PHARMACOGENOMICS REVEALS ERBB2 AS A THERAPEUTIC TARGET IN PRIMARY EPENDYMOMA CULTURES. Neuro-Oncology, 2019, 21, ii78-ii79.	1.2	0
18	Recurrent noncoding U1ÂsnRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature, 2019, 574. 707-711.	27.8	129

Claudia C Faria

#	Article	IF	CITATIONS
19	BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas. BMC Cancer, 2018, 18, 1259.	2.6	26
20	A functional genomics approach to identify pathways of drug resistance in medulloblastoma. Acta Neuropathologica Communications, 2018, 6, 146.	5.2	10
21	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
22	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
23	Lumbar pseudo-tail associated with dermal sinus – A case report. Neurocirugia, 2017, 28, 294-297.	0.4	3
24	Imaging mass spectrometry identifies prognostic ganglioside species in rodent intracranial transplants of glioma and medulloblastoma. PLoS ONE, 2017, 12, e0176254.	2.5	13
25	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	16.8	191
26	Pediatric central nervous system tumors: review of a single Portuguese institution. Child's Nervous System, 2016, 32, 1227-1236.	1.1	9
27	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
28	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
29	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
30	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Research, 2015, 75, 134-146.	0.9	51
31	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget, 2015, 6, 3359-3374.	1.8	23
32	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. Oncotarget, 2015, 6, 21718-21729.	1.8	26
33	Duration of the preâ€diagnostic interval in medulloblastoma is subgroup dependent. Pediatric Blood and Cancer, 2014, 61, 1190-1194.	1.5	42
34	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
35	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
36	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146

Claudia C Faria

#	Article	IF	CITATIONS
37	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
38	Pediatric brain tumors: genetics and clinical outcome. Journal of Neurosurgery: Pediatrics, 2010, 5, 263-270.	1.3	23
39	Genetic alterations in a papillary glioneuronal tumor. Journal of Neurosurgery: Pediatrics, 2008, 1, 99-102.	1.3	33